Tarlatamab

IMDELLTRA is indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: IMDELLTRA is indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

Side effects, and when to stop

The following clinically significant adverse reactions are described elsewhere in the labeling:

Cytokine Release Syndrome (CRS)
Neurologic Toxicity Including ICANS
Cytopenias
Infections
Hepatotoxicity
Hypersensitivity

Who should not take it

None.

Storing it

Store IMDELLTRA and IV Solution Stabilizer (IVSS) vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of use. Do not freeze.

IMDELLTRA and IV Solution Stabilizer (IVSS) vials may be kept at room temperature between 20°C to 25°C (68°F to 77°F) for up to 24 hours in the original carton to protect from light.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Tarlatamab; [reviewed 2026 Aug 3; cited 2026 Nov 11]. Available from: https://sofidex.com/patients/medicines/tarlatamab
APA 7th: sofidex. (2026, August 3). Tarlatamab. Daloreum. Retrieved November 11, 2026, from https://sofidex.com/patients/medicines/tarlatamab
AMA 11th: Tarlatamab. sofidex. Reviewed August 3, 2026. Accessed November 11, 2026. https://sofidex.com/patients/medicines/tarlatamab

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.